FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. PMID 39756446 · Lancet Oncol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. PMID 39753962 · Nat Med · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80). PMID 39710508 · J Gynecol Oncol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of locoregional recurrence versus distant metastasis on overall survival in patients with Non-Small cell lung cancer after Surgery: A secondary analysis of PORT-C RCT. PMID 39700682 · Lung Cancer · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial. PMID 39671779 · Gynecol Oncol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults. PMID 39652202 · Eur J Drug Metab Pharmacokinet · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial. PMID 39644535 · Eur J Cancer · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of probiotics on clinical manifestations and inflammatory markers in HTLV-1-associated myelopathy/tropical spastic paraparesis: A triple blind randomized, placebo controlled trial. PMID 39631261 · Cytokine · 2025-Jan The study is a randomized controlled trial of a probiotic intervention for HTLV-1-associated myelopathy/tropical spastic paraparesis, which is a neurological condition, not a malignant neoplasm (oncology). It does not report a time-to-event efficacy endpoint (OS, PFS, etc.). The phase is not specified as Phase III/IIIb. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014). PMID 39615333 · Eur J Cancer · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. PMID 39612919 · Lancet Oncol · 2025-Jan The trial is oncology, human, randomized, phase 3, and has a drug intervention with a primary result report. However, the primary and only reported efficacy endpoint is pathological complete response (pCR), a binary endpoint. There is no evidence of a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with associated KM data or HR, which is required for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission. PMID 39606837 · Future Oncol · 2025-Jan The record is a protocol for a randomized, open-label trial (REGAL) of galinpepimut-S in AML. It is oncology, human, randomized, involves a drug intervention, and is an original protocol document. However, it is not an original result report, does not present any efficacy data or time-to-event endpoints, and is a protocol, not a results publication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. PMID 39602990 · Eur J Cancer · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. PMID 39586309 · Lancet Diabetes Endocrinol · 2025-Jan While the study meets most criteria (oncology, human, randomized, phase 3, drug intervention, original results), it is ineligible because the primary efficacy endpoint is a binary proportion (event-free proportion at 5 years) for non-inferiority assessment, not a time-to-event endpoint suitable for Kaplan-Meier digitization (e.g., OS, PFS, DFS with time-to-event analysis or hazard ratio). The deterministic review's 'no_time_to_event_signal' is correct. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. PMID 39571587 · Lancet Gastroenterol Hepatol · 2025-Jan The record describes a randomized, double-blind, Phase III trial of vedolizumab for Crohn's disease recurrence. While it meets criteria for being a human, randomized, Phase III drug-intervention trial with original results, it is excluded because it is non-oncology (Crohn's disease) and the primary endpoint is not a time-to-event efficacy outcome (it is a categorical endoscopic score). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer. PMID 39546932 · Gynecol Oncol · 2025-Jan Study is an oncology randomized trial with human participants and reports primary results, but is excluded because it involves a non-drug intervention (online support group) and lacks a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). No drug-containing intervention is present. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer. PMID 39546931 · Gynecol Oncol · 2025-Jan The record is a biomarker subgroup analysis of a randomized trial, not the primary report of a Phase III/IIIb or Phase II/III drug efficacy trial. The trial phase is not definitively established in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nutritional support after hospital discharge reduces long-term mortality in patients after gastric cancer surgery: Secondary analysis of a prospective randomized trial. PMID 39541610 · Nutrition · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial. PMID 39527970 · Lancet Gastroenterol Hepatol · 2025-Jan 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer. PMID 39522824 · Radiother Oncol · 2025-Jan The report is a secondary analysis of protocol compliance in a phase III randomized trial for head and neck cancer. While it is oncology, human, randomized, and phase III, it does not meet eligibility because: (1) the intervention is radiotherapy-based (non-drug-only), (2) the analysis is not a primary report of a time-to-event efficacy endpoint (locoregional control is mentioned but no time-to-event data like Kaplan-Meier or HR are reported), and (3) the focus is on quality assurance and protocol adherence rather than primary efficacy results. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur Urol. 86(1) (2024) 52-60]. PMID 39521695 · Eur Urol · 2025-Jan Record is a published erratum (corrigendum) to an original trial report. The abstract is empty, and no data on study population, interventions, or outcomes are provided in the record. While the title references a Phase 3 randomized trial (PSMA-SRT) with an imaging intervention (PSMA-PET/CT) for prostate cancer, it does not explicitly describe a drug-containing intervention or a time-to-event efficacy endpoint. The publication type 'Published Erratum' and lack of results content exclude it as an original result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial. PMID 39506903 · Muscle Nerve · 2025-Jan 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01. PMID 39482146 · Clin Lung Cancer · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial. PMID 39481606 · Radiother Oncol · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series. PMID 39434457 · Br J Haematol · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Short-term results of unroofing and marsupialization compared to the Karydakis technique in the treatment of pilonidal sinus. A randomized prospective study. PMID 39427709 · Cir Esp (Engl Ed) · 2025-Jan 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. PMID 39379236 · Eur Urol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical trial design for novel targeted agents in neuro-oncology. PMID 39377992 · J Neurooncol · 2025-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial. PMID 39375287 · Int J Clin Oncol · 2025-Jan The study is a single-arm (non-randomized) Phase III trial evaluating diagnostic accuracy (sensitivity) and safety of photodynamic diagnosis in bladder cancer. While it is oncology, human, Phase III, involves a drug (5-ALA), and reports original results, it fails two critical eligibility criteria: it is not randomized, and its primary endpoint is a diagnostic accuracy measure (sensitivity), not a time-to-event efficacy endpoint like OS, PFS, DFS, or similar. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome. PMID 39367118 · Ann Hematol · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial. PMID 39353160 · J Clin Oncol · 2025-Jan The study is a cluster-randomized trial of a screening intervention (EBV antibody testing) for nasopharyngeal carcinoma mortality, not a randomized trial of a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Is it time to say goodbye to drainage after axillary lymph node dissection in breast cancer? A randomized clinical trial of systemic tranexamic acid combined with topical epinephrine + xylocaine versus conventional drainage. PMID 39327927 · Trop Doct · 2025-Jan Eligibility requires a definitive-phase (Phase III/IIIb or II/III) randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). While this is an oncology RCT with a drug intervention, it is not a Phase III/IIIb or Phase II/III trial (phase not stated, but primary endpoint is seroma rate, a non-time-to-event outcome). Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. PMID 39313156 · Ann Oncol · 2025-Jan The study is a secondary biomarker analysis from phase III randomized trials. It does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, HR, or Kaplan-Meier curves) and is therefore ineligible for this Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen. PMID 39307840 · Br J Clin Pharmacol · 2025-Jan The MIRASOL trial is explicitly described as a confirmatory, randomized, chemotherapy-controlled trial in platinum-resistant ovarian cancer, which meets the criteria for a definitive Phase III trial with a drug intervention and primary time-to-event endpoints (PFS, OS). The abstract reports original results supporting this. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Platelet-rich Plasma as an Adjuvant Therapy to Crystallized Phenol in the Treatment of Pediatric Pilonidal Sinus Disease: A Prospective Randomized Controlled Trial. PMID 39307596 · J Pediatr Surg · 2025-Jan 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa. PMID 39301921 · Prostate · 2025-Jan The record describes a subanalysis from a randomized controlled trial with time-to-event endpoints (OS, TTPP) and drug interventions (enzalutamide, abiraterone), meeting several criteria. However, it is explicitly a 'subanalysis' and not the primary report of a Phase III or definitive trial; the phase is not explicitly established in the provided metadata as Phase III/IIIb or Phase II/III, and the analysis is a pre-specified subanalysis comparing dose modifications, not the main trial result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous versus intravenous nivolumab for renal cell carcinoma. PMID 39288844 · Ann Oncol · 2025-Jan The study is a Phase III randomized trial with a drug intervention in oncology, but the primary and key secondary endpoints are pharmacokinetic parameters and objective response rate, respectively. There is no mention of a time-to-event efficacy endpoint such as OS, PFS, DFS, or HR in the provided abstract. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia. PMID 39284116 · J Clin Oncol · 2025-Jan The record describes a randomized, controlled, human oncology trial with drug intervention and time-to-event efficacy endpoints (OS, RFS). However, the provided metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. Therefore, eligibility cannot be confirmed without this information. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo. PMID 39243988 · Brain Behav Immun · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration. PMID 39230186 · Clin Pharmacol Drug Dev · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. PMID 39133306 · Eur J Nucl Med Mol Imaging · 2025-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adenoma detection rate and tolerability of 2 ultra-low-volume bowel preparations in screening: a noninferiority randomized controlled trial. PMID 39069266 · Gastrointest Endosc · 2025-Jan The study is an oncology-related randomized trial but fails two key eligibility criteria: (1) The intervention is not a drug-containing anti-cancer treatment; it compares bowel cleansing preparations for colonoscopy in a screening program. (2) The primary endpoint is adenoma detection rate, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it is not eligible for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation. PMID 38992106 · Eur Radiol · 2025-Jan The study is a randomized, multicenter prospective diagnostic accuracy trial comparing imaging modalities for hepatocellular carcinoma (oncology, human, randomized). However, it is excluded because: 1) it is not a Phase III/IIIb or definitive Phase II/III randomized trial (no phase is specified, and the design is a diagnostic accuracy study, not a therapeutic efficacy trial), 2) there is no drug-containing intervention (the intervention is locoregional therapies, not a drug regimen), and 3) there is no time-to-event efficacy endpoint (the primary outcome is diagnostic performance metrics like sensitivity, specificity, and AUC, not survival outcomes). Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis. PMID 38857908 · J Gynecol Oncol · 2025-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunocyte profiling changes in patients received epidural versus intravenous analgesia after pancreatectomy: A randomized controlled trial. PMID 38494360 · J Formos Med Assoc · 2025-Jan The trial is randomized and reports time-to-event efficacy endpoints (PFS, OS). However, the intervention compares analgesia techniques (epidural vs. IV patient-controlled analgesia), which is a non-drug-only intervention. It does not involve a systemic drug intervention (e.g., chemotherapy, targeted therapy, immunotherapy) as required for eligibility. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hyperthermic intraperitoneal chemotherapy plus SOX chemotherapy versus SOX chemotherapy alone in patients with gastric cancer and peritoneal metastasis: a phase II randomized clinical trial. PMID 40115934 · J Gastrointest Oncol · 2025-Feb-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Partial pressure of oxygen control versus modified inflation-deflation method in identifying intersegmental plane during anatomical sublobectomy: a prospective, randomized, controlled trial. PMID 40083504 · J Thorac Dis · 2025-Feb-28 Study is a randomized trial in oncology (NSCLC surgical technique) but fails key eligibility criteria: not a drug intervention trial (compares PaO2 control vs. modified inflation-deflation methods for ISP identification), not phase III/definitive (phase not specified, appears to be a surgical technique comparison trial), and lacks time-to-event efficacy endpoint (primary outcome is time to ISP appearance, not OS/PFS/DFS etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up. PMID 40022029 · BMC Cancer · 2025-Feb-28 The record describes a randomized trial of radiotherapy in breast cancer, which is oncological and human, with a time-to-event endpoint (ipsilateral breast tumor recurrence). However, the intervention is radiotherapy, not a drug. The trial is not a Phase III/IIIb or Phase II/III drug trial. The study is a secondary analysis investigating a biomarker's predictive value, not a primary efficacy report of a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Longitudinal circulating tumor DNA monitoring in predicting response to short-course radiotherapy followed by neoadjuvant chemotherapy and camrelizumab in locally advanced rectal cancer: data from a Phase Ⅲ clinical trial (UNION). PMID 39755361 · Cancer Lett · 2025-Feb-28 The study is a Phase III RCT with a drug intervention, but the primary endpoint is pathological complete response (pCR), a binary outcome, not a time-to-event endpoint. No OS, PFS, or other time-to-event efficacy data are reported in the provided information. |
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multi-centre, participant-blinded, randomized, 3-year study to compare the efficacy of Virtual Surgical Planning (VSP) to Freehand Surgery (FHS) on bony union and quality of life outcomes for mandibular reconstruction with fibular and scapular free flaps: study protocol for a randomized phase II/III trial. PMID 40016641 · BMC Cancer · 2025-Feb-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial. PMID 40014335 · JAMA Oncol · 2025-Feb-27 The title indicates a Phase 3 randomized trial in oncology, but the provided metadata (title only) lacks explicit signals for a drug intervention (e.g., enzalutamide, abiraterone), a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.), or confirmation that this is an original result report (vs. biomarker or correlative analysis). Without the full text, eligibility cannot be established. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |